Skip to content

Clinical study of Baoshen formula delaying the progression of diabetic nephropathy

Integrated development of active components of Baoshen prescription in the treatment of chronic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053509
Enrollment
Unknown
Registered
2021-11-23
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Group 1:Baoshen Fang
Group 3:Baoshen Fang+Irbesartan

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, gender is not limited; 2. Diabetic nephropathy stage II to III patients; 3. Blood pressure can be effectively controlled; 4. Voluntary participation in research.

Exclusion criteria

Exclusion criteria: 1. Patients with primary and secondary chronic kidney disease; 2. Those who did not take ACEI/ARB within 1 month before entering the study and Chinese herbal medicines containing rhubarb, astragalus, saffron, etc.; 3. Combined with mental illness or unwilling to take Chinese herbal medicine; 4. Those with acute infection recently; 5. Severe digestive tract diseases, such as active ulcers, chronic diarrhea, gastrointestinal surgery, etc.; 6. Patients with diseases of the heart, brain, liver and hematopoietic system; 7. Patients with essential hypertension; 8. Combined with ketoacidosis and lactic acidosis; 9. Patients who are pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Urine protein quantification at 24 hours;The biochemical indicators;Blood coagulation indexes;

Countries

China

Contacts

Public ContactWang Jianqin
wangjianqin@medmail.com.cn+86 13919038189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026